May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Bevacizumab-Enhanced Photodynamic Therapy in Exudative Age-Related Macular Degeneration: 6 Months Follow-Up
Author Affiliations & Notes
  • A. Navea
    Retina., Fundacion Oftalmologica del Mediterraneo, Valencia, Spain
  • C. Desco
    Retina., Fundacion Oftalmologica del Mediterraneo, Valencia, Spain
  • E. Palacios
    Retina., Fundacion Oftalmologica del Mediterraneo, Valencia, Spain
  • J. Mataix
    Retina., Fundacion Oftalmologica del Mediterraneo, Valencia, Spain
  • M. Garcia-Pous
    Retina., Fundacion Oftalmologica del Mediterraneo, Valencia, Spain
  • Footnotes
    Commercial Relationships A. Navea, None; C. Desco, None; E. Palacios, None; J. Mataix, None; M. Garcia-Pous, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1824. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Navea, C. Desco, E. Palacios, J. Mataix, M. Garcia-Pous; Bevacizumab-Enhanced Photodynamic Therapy in Exudative Age-Related Macular Degeneration: 6 Months Follow-Up. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1824.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To determine whether intravitreal bevacizumab improves the efficacy of photodynamic therapy (PDT) with verteporfin in subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Methods:: Prospective interventional study. 55 patients with AMD were included and treated with combined photodynamic therapy and intravitreal injection of bevacizumab (1.25mg). Patients underwent best-corrected ETDRS visual acuity testing, optical coherence tomography, angiofluoresceingraphy and ophthalmoscopic examination at baseline and follow-up visits at 3 and 6 months. Visual acuity and OCT were performed monthly. Retreatment was made with intravitreal injection of bevacizumab in early reactivations and photodynamic therapy with verteporfin was associated if the reactivation was in the 3rd or 6th month visit

Results:: at six months follow-up, 38% of the patients received only one treatment. The mean number of treatments for every patient was 1.5 intravitreal bevacizumab and 1.17 photodynamic therapies. At six month follow-up, 90% of the cases didn’t need more treatment

Conclusions:: The combination of PDT and intravitreal bevacizumab may increase the possibility of improving or stabilizing visual acuity in patients with exudative age-related macular degeneration. The mean number of treatment sessions following combination therapy of intravitreal bevacizumab (1.5mg) and PDT appears relatively less compared to PDT or anti-VEGF alone, but further studies are needed to asses the effects of this treatment.

Keywords: age-related macular degeneration • photodynamic therapy • choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×